A drug called Imlygic that relies upon a genetically engineered herpes virus to attack and kill the cancerous cells has been approved by the Food and Drug Administration (FDA). It is the first virotherapy to get approval for the treatment of skin cancer or melanoma.
Though virus has been used to treat various kinds of diseases for decades, the ability of virus to shrink tumors is still unsure. In a recent study that was conducted on 400 patients with metastatic melanoma, the drug Imylgic showed positive results by shrinking the tumors.
People With Advance Melanomas Heave a Sigh of Relief With a New Drug in UK
Pembrolizumab drug works by making cancer cells visible to the body's immune system so it can be attacked by its own natural defence mechanisms.
Advertisement
Metastatic melanoma affects around 10,000 people every year in the US and it results in the formation of lesions on the skin and lymph nodes.
When the drug was injected into the patient, the herpes virus identified the tumor cells and invaded it. It caused the tumor cells to burst leaving the tumor shrunk and also sent signals to the immune system. Though, it caused flu-like symptoms in patients, it was milder. The drug extended survival time by 4.4 months and shrunk tumors in more than 16 percent of patients. This new technique creates hopes for developing many more virotherapies for the treatment of various other late-stage cancers.
Source: Medindia
Source: Medindia
Splurge on Vitamin B3 Rich Diet to Reduce Risk of New Non-Melanoma Skin Cancer
Nicotinamide reduced the incidence of new non-melanoma skin cancers by 23 percent and cut the incidence of pre-cancerous sun spots by 15 percent.
Advertisement
 Apple's Latest ResearchKit to Study Autism, Epilepsy and MelanomaResearchKit will allow more people to participate in clinical trials that will provide more data that are crucial for studying how and why certain diseases occur. | Advertisement
|
Follow These Simple Tips by a Cuban-American Expert to Keep Skin Cancer at Bay
One should never be unprotected during the middle of the day, from about 10 am until 4 pm. Research shows a simple white T-shirt is not enough.
Advertisement
Recommended Readings
Latest Cancer News
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
